Trails Edge Capital Partners LP Makes New $10.25 Billion Investment in Aura Biosciences, Inc. $AURA

Key Points

• Trails Edge Capital Partners acquired 1.44 million Aura Biosciences shares valued at approximately $10.25 billion, representing about 1.39% of the company and 1.6% of the fund’s holdings.
• Aura Biosciences reported a quarterly loss of $0.48 per share, missing analyst estimates of a $0.38 loss. Analysts expect a full-year loss of approximately $1.61 per share.
• AURA opened at $7.82, while analyst opinions remain mixed: two analysts rate it Buy and one Sell, resulting in a consensus Hold rating and a $17.50 price target.

Trails Edge Capital Partners LP acquired a new stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,443,333 shares of the company's stock, valued at approximately $10,247,665,000. Aura Biosciences makes up about 1.6% of Trails Edge Capital Partners LP's holdings, making the stock its 24th largest holding. Trails Edge Capital Partners LP owned about 1.39% of Aura Biosciences as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in AURA. Legal & General Group Plc bought a new stake in shares of Aura Biosciences during the second quarter worth about $29,000. Parallel Advisors LLC lifted its position in Aura Biosciences by 130.4% in the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock valued at $38,000 after acquiring an additional 3,206 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after acquiring an additional 2,104 shares in the last quarter. ProShare Advisors LLC acquired a new position in Aura Biosciences during the 4th quarter valued at about $59,000. Finally, Water Island Capital LLC acquired a new position in Aura Biosciences during the 3rd quarter valued at about $64,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Price Performance

AURA opened at $7.82 on Wednesday. Aura Biosciences, Inc. has a fifty-two week low of $4.73 and a fifty-two week high of $9.53. The firm has a market capitalization of $811.01 million, a P/E ratio of -4.47 and a beta of 0.40. The company's 50-day moving average is $7.23 and its 200 day moving average is $6.86.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). On average, equities research analysts expect that Aura Biosciences, Inc. will post -1.61 earnings per share for the current year.

Insider Buying and Selling at Aura Biosciences

In other news, insider Anthony S. Gibney sold 12,824 shares of the company's stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total value of $82,330.08. Following the completion of the transaction, the insider directly owned 265,354 shares of the company's stock, valued at $1,703,572.68. This represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AURA shares. Wall Street Zen downgraded Aura Biosciences from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. HC Wainwright cut their target price on Aura Biosciences from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings upgraded Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 14th. Finally, Leerink Partners set a $17.00 price target on Aura Biosciences in a research report on Tuesday, May 12th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Aura Biosciences has a consensus rating of "Hold" and a consensus price target of $17.50.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

Want to see what other hedge funds are holding AURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aura Biosciences, Inc. (NASDAQ:AURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source